Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Nebius Aktie 12955842 / NL0009805522

06.11.2025 08:00:14

Nebius AI Cloud arrives in UK with one of the country’s first advanced NVIDIA AI infrastructure deployments

Nebius Group
Nebius AI Cloud arrives in UK with one of the country’s first advanced NVIDIA AI infrastructure deployments

06-Nov-2025 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Nebius AI Cloud arrives in UK with one of the country’s first advanced NVIDIA AI infrastructure deployments

 

  • New facility featuring NVIDIA Blackwell Ultra GPUs and NVIDIA Quantum-X800 InfiniBand networking is one of the UK’s most advanced AI supercomputing platforms

 

London, November 6, 2025Nebius (NASDAQ: NBIS) today unveiled its first deployment of NVIDIA Blackwell Ultra AI infrastructure in the UK, bringing the supercomputer power and hyperscaler simplicity of Nebius AI Cloud to UK customers from locally deployed specialized AI compute.

 

Powered by NVIDIA Blackwell Ultra GPUs and NVIDIA Quantum-X800 InfiniBand networking, the deployment delivers unprecedented performance for generative AI and future foundation model development. It is the latest milestone in Nebius’s global build-out, following similar deployments of high-performance AI infrastructure across Europe, the US and Israel.

 

The launch expands the UK’s domestic compute capacity, supporting the goals set out in the UK Government's AI Opportunities Action Plan and enabling British businesses, researchers, and public services to build and deploy AI at scale.

 

Arkady Volozh, founder and CEO of Nebius, said:

 

“This launch is a milestone for Nebius and for the UK’s growing AI ecosystem. By combining our cloud infrastructure foundations with NVIDIA’s latest technology, we’re empowering organizations across the UK to train, deploy, and scale AI models and applications faster, more securely, and more sustainably than ever.”

 

Anthony Hills, Regional Director Enterprise Business, UK&I at NVIDIA, said:

 

“The UK’s industrial future is being reshaped by AI. With Nebius deploying advanced AI infrastructures, built on the NVIDIA accelerated computing platform, we are helping to unlock the potential of British data to drive innovation, fuel economic growth, and strengthen national resilience.”

 

Innovative companies will be able to tap Nebius’s UK capacity to develop new frontier models and AI solutions. Nebius supports builders across the entire UK AI ecosystem, from startups to enterprises and from academia to the NHS, and across key industries including healthcare and pharma, life sciences, fintech, robotics and physical AI.

 

Among the first partners for the deployment is Basecamp Research, which uses AI to tackle unsolved frontier challenges in the life sciences industry.

 

Basecamp Research co-founder Oliver Vince said:

 

"Tackling unprecedented challenges like designing programmable medicines requires infrastructure that can handle massive proprietary datasets from across the globe while maintaining the speed and reliability to push scientific boundaries. Nebius's infrastructure delivers the scale and performance we need; having it here in the UK means we keep greater control over our data and can compete at the cutting edge of AI-driven life sciences.”

 

Prima Mente, an AI neuroscience company, uses Nebius infrastructure to develop models that enable potential new treatments for brain diseases including Alzheimer’s and Parkinson’s.

 

Prima Mente founder and CEO Ravi Solanki said:

 

"Training multi-billion parameter foundation models on biological data demands infrastructure that can scale rapidly without breaking our workflow. Nebius enables us to spin up dozens of experiments simultaneously, accelerating our mission to decode the mechanisms behind Alzheimer's and Parkinson's. Having this performance available locally means we can deliver better diagnostics for patients across the UK faster."

 

Located at a state-of-the-art facility in the London area, Nebius’s UK deployment integrates advanced energy-efficient cooling technologies, low-latency NVIDIA Quantum-X800 InfiniBand network connectivity, and resilient on-site power generation. It features NVIDIA Blackwell Ultra GPUs, delivering unprecedented performance for generative AI and future foundation model development. The collaboration between Nebius and NVIDIA allows for full integration with the NVIDIA AI Enterprise software suite to support enterprise-grade scalability and efficiency.

 

Nebius AI Cloud 3.0 “Aether”, the latest evolution of Nebius’s platform, is designed to meet the demands of next-generation AI in contexts including healthcare, finance, life sciences, enterprise, and government. With enterprise-grade features including SOC2 Type II certification including HIPAA, end-to-end encryption and full compliance with GDPR and CCPA data protection standards, Aether gives organizations the trust, control, and simplicity they need to run their most critical AI workloads in production and at scale.

 

A Reference Platform NVIDIA Cloud Partner (NCP), Nebius delivers AI-accelerated services built on the NCP reference architecture, as well as providing strategic value and regional impact through close collaboration with NVIDIA for enablement and support. Nebius is also among the first NCPs to achieve Exemplar Cloud for training workloads on NVIDIA Hopper GPUs, demonstrating workload performance to within 95% of NVIDIA’s reference architecture.

Additional resources

About Nebius

 

Nebius is a technology company building full-stack cloud infrastructure for the global AI industry. Headquartered in Amsterdam and listed on Nasdaq (NASDAQ: NBIS), the company has a global footprint with R&D hubs across Europe, North America, and Israel.

 

Nebius AI Cloud has been built from the ground up for intensive AI workloads. With proprietary software and hardware designed in-house, Nebius gives AI builders the compute, storage, managed services, and tools they need to build, tune, and run their models.

Contacts

Investor Relations: askIR@nebius.com
Media Relations: media@nebius.com

 

Disclaimer

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the potential technical and commercial success of our operations in the United Kingdom,  are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “guide,” “intend,” “likely,” “may,” “will” and similar expressions and their negatives are intended to identify forward-looking statements.
 

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. Actual results may differ materially from the results predicted or implied by such statements, and our reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others: market, macroeconomic and geopolitical conditions; our ability to build, operate and manage our businesses in the United Kingdom, competitive pressures; technological developments; our ability to secure and retain clients; our ability to secure additional capital to enable the growth of the business; unpredictable sales cycles; and potential pricing pressures; as well as those risks and uncertainties related to our continuing businesses included under the captions “Risk Factors” and “Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on April 30, 2025.
 

All information in this press release is as of the date hereof (unless stated otherwise). Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

View original content: EQS News


End of Announcement - EQS News Service

2224548  06-Nov-2025 

Analysen zu Nebius

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’465.39 10.11.2025 17:30:00
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

Nebius 88.44 3.16% Nebius

Nebius am 06.11.2025

Chart